GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » E10

Actinium Pharmaceuticals (STU:7AY1) E10 : €-7.57 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Actinium Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was €-0.333. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-7.57 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 24.40% per year. During the past 5 years, the average E10 Growth Rate was 16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Actinium Pharmaceuticals was 24.40% per year. The lowest was -4.50% per year. And the median was -1.30% per year.

As of today (2025-03-23), Actinium Pharmaceuticals's current stock price is €1.272. Actinium Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was €-7.57. Actinium Pharmaceuticals's Shiller PE Ratio of today is .


Actinium Pharmaceuticals E10 Historical Data

The historical data trend for Actinium Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals E10 Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.11 -23.68 -22.78 -11.27 -9.79

Actinium Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.84 -9.79 -8.66 -8.58 -7.57

Competitive Comparison of Actinium Pharmaceuticals's E10

For the Biotechnology subindustry, Actinium Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Shiller PE Ratio falls into.



Actinium Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Actinium Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.333/133.0289*133.0289
=-0.333

Current CPI (Sep. 2024) = 133.0289.

Actinium Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201412 -4.136 99.070 -5.554
201503 -2.495 99.621 -3.332
201506 -5.346 100.684 -7.063
201509 -2.673 100.392 -3.542
201512 -4.406 99.792 -5.873
201603 -2.694 100.470 -3.567
201606 -3.738 101.688 -4.890
201609 -3.742 101.861 -4.887
201612 -3.413 101.863 -4.457
201703 -3.927 102.862 -5.079
201706 -3.204 103.349 -4.124
201709 -2.265 104.136 -2.893
201712 -1.521 104.011 -1.945
201803 -1.703 105.290 -2.152
201806 -1.027 106.317 -1.285
201809 -1.543 106.507 -1.927
201812 -1.319 105.998 -1.655
201903 -1.328 107.251 -1.647
201906 -0.884 108.070 -1.088
201909 -1.099 108.329 -1.350
201912 -0.720 108.420 -0.883
202003 -0.887 108.902 -1.084
202006 -0.364 108.767 -0.445
202009 -0.306 109.815 -0.371
202012 -0.304 109.897 -0.368
202103 -0.244 111.754 -0.290
202106 -0.208 114.631 -0.241
202109 -0.255 115.734 -0.293
202112 -0.319 117.630 -0.361
202203 -0.209 121.301 -0.229
202206 -0.312 125.017 -0.332
202209 -0.384 125.227 -0.408
202212 -0.406 125.222 -0.431
202303 -0.402 127.348 -0.420
202306 -0.535 128.729 -0.553
202309 -0.459 129.860 -0.470
202312 -0.303 129.419 -0.311
202403 -0.285 131.776 -0.288
202406 -0.353 132.554 -0.354
202409 -0.333 133.029 -0.333

Add all the adjusted EPS together and divide 10 will get our e10.


Actinium Pharmaceuticals  (STU:7AY1) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Actinium Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals Headlines

No Headlines